The Latest News
FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray, an investigational product for the acute treatment of seizure clusters>
Midazolam Nasal Spray has been granted orphan drug designation by the United States Food and Drug Administration (US FDA) for the rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity.
ElectroCore, Inc. Announces Research Collaboration with Massachusetts General Hospital to Explore Non-Invasive Vagus Nerve Stimulation in Neuroinflammation>
Non-invasive vagus nerve stimulation (nVNS) will be studied in preclinical settings, looking at the effects of this novel therapeutic approach on neuroinflammatory mechanisms which have been associated with conditions in the central nervous system (CNS) including pain, trauma and neurodegeneration.
Next Generation nVNS Therapy gammaCore Sapphire™ Now Available for Patients with Migraine and Episodic Cluster Headache in United States>
Innovative technology provides patients with convenient, easy-to-use treatment option without the potential side effects associated with commonly prescribed medicines
ElectroCore and UpScript Launch Program to Offer Direct-to-Patient Telemedicine Option for gammaCore™ in the United States>
gammaCore is the first FDA-cleared, nVNS therapy that can be self-administered by patients as needed for the acute treatment of pain associated with migraine and episodic cluster headache. UpScript offers a convenient way for prospective patients to consult with a licensed healthcare provider via telephone or video to find out if they are candidates for gammaCore.
Authors conclude novel delivery devices should be developed in conjunction with CAR-T therapies
VERASENSE™ Sensor-Assisted Technology Now Approved for Use with Zimmer Biomet Persona® Knee System, enabling surgeons to improve knee balance and customize implant position during surgery by using intraoperative sensor data.
Exagen Diagnostics announces collaboration with GSK to drive greater awareness about challenges facing lupus diagnosis and management>
Shared goal to help SLE patients shorten the time to their diagnosis, which is nearly six years on average, and to facilitate improved patient health outcomes
Szela brings nearly 30 years of progressive leadership experience to Surefire building global billion-dollar brands, advancing pipeline products in the biotechnology, medical products, and pharmaceutical industries while creating value for stakeholders.
Latest EPAD™ System innovation reduces false positive alerts during surgical nerve monitoring
National Rheumatology Group AARA Embraces Exagen Diagnostics' Novel Method to Collect and Test for Widely Used Therapies in Lupus and Rheumatoid Arthritis>
Novel AVISE Touch capillary blood collection method eliminates the need for venipuncture blood draw
OrthoSensor to be recognized at Edison Awards Gala on April 20 in New York
OrthoSensor, Inc., the leader in sensor-assisted total knee arthroplasty, and IM-Tech, a subsidiary of Woori ETI Co., Ltd. a leading company in electronic components for telecommunications and consumer electronics industries, entered into a strategic partnership agreement that includes research and development collaboration, manufacturing, and capital investment.
Surefire Medical Launches Advanced Precision Direct-To-Tumor Infusion System at CIRSE
Two Members of the Tullis Health Investors Advisory Board, Dr. David Leffell and Dr. Barbara Bierer, Become Venture Partners>
Tullis Health Investors is pleased to announce that Dr. David Leffell, Chair of the Tullis Health Investors Advisory Board, and Dr. Barbara Bierer, a long-time member of the Board, have each taken additional responsibilities as Venture Partners of Tullis.
In June 2015, Tullis Growth Fund, L.P. (TGF) closed an investment into Surefire Medical. The company develops, manufactures, and markets medical devices, in particular catheters to precisely deliver therapeutic drugs in liver cancer patients.
Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases.
We are pleased to announce that Professor Das Narayandas, BTech, PGDM, PhD, has joined the Advisory Board of Tullis Health Investors. Das Narayandas is the James J. Hill Professor of Business Administration at the Harvard Business School. He is currently the Senior Associate Dean, Chair, Harvard Business Publishing, and Senior Associate Dean, Chair, Executive Education.
The Tullis Growth Fund has completed its second investment into Orthosensor, a Florida-based maker of knee and joint implant placement technologies.